uploads///Mednax Analysts Reco

The Latest Wall Street Recommendations for Mednax


Dec. 13 2017, Updated 4:53 p.m. ET


Analysts’ ratings for Mednax

Of the total 14 analysts covering Mednax (MD) in December 2017, three analysts have given the stock a “buy” or higher rating and ten have given it a “hold” rating while one analyst has given it a “sell” rating. The mean rating for the stock is 2.71 with a mean target price of $48.18.

Notably, Mednax makes up about 0.26% of the iShares Core S&P Mid-Cap ETF’s (IJH) total portfolio holdings.

Article continues below advertisement

Peer ratings

Of the 20 analysts covering Lifepoint Health (LPNT) in December 2017, five analysts have given the stock a “buy” or higher rating and two analysts have given it a “sell” or lower rating. For Acadia Healthcare Company (ACHC), of the 17 analysts covering the company, ten have given the stock a “buy” or higher rating. Meanwhile, of the 15 analysts covering Envision Healthcare (EVHC), 11 have given it a “buy” or higher rating and five analysts have given it a “hold” rating.

In the next part of this series, we take a look at Mednax’s business strategy.


More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.